A scheme to solve the seemingly intractable problem of creating a viable market for companies developing novel antimicrobials has got underway in the UK, with antibiotics from Pfizer Inc. and Shionogi & Co. Ltd. leading the charge.
Pfizer And Shionogi Form Vanguard In New Subscription Assault On Antibiotic Resistance
Deals Signed With UK’s NHS Pilot Scheme
Two antibiotics from Pfizer and Shionogi are to be rolled out by the UK’s NHS in a pioneering subscription deal that hopes to encourage antibiotic R&D by delinking payment from volume of use.
